About
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel,...
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.

Executive Management :

Dr. Carlos De Sousa ( Chief Executive Officer )
Dr. Peter Sunaert ( Chief Medical Officer )
Mrs. Michaela Gertz ( Chief Financial Officer )
Dr. Alex Karlsson-Parra ( Chief Scientific Officer )
Dr. Sharon Longhurst ( Head of CMC )
Mrs. Margareth Jorvid ( Head of Regulation and QA )
Mr. Sijme Zeilemaker ( Senior Director Business Development )

Board of Directors :

Mr. Michael Oredsson ( Chairman )
Dr. Magnus Nilson ( Director )
Dr. Charlotte Edenius ( Director )
Prof. Magnus Persson ( Director )
Dr. Steven Glazer ( Director )
Mrs. Kerstin Valinder Strinnholm ( Director )